Recently, the Supreme People’s Court of China (SPC) upheld a decision of the Beijing Intellectual Property Court reversing a China National Intellectual Property Administration (CNIPA) invalidation decision and confirming the validity of Novo Nordisk’s semaglutide compound patent. Although the final written decision has not yet been publicly released, official summaries indicate that the court accepted post-filing experimental data where “the technical effect can be derived from the original specification” (技术效果可由原说明书得出), reversing an administrative invalidation decision. Public reporting further indicates that the dispute turned on whether CNIPA would accept post-filing experimental data demonstrating semaglutide’s surprising pharmacokinetic effects in animal models, where the application as filed contained no experimental data.